Bitter gourd inhibits the development of obesity-associated fatty liver in C57BL/6 mice fed a high-fat diet

Journal of Nutrition

Volumn 144, Issue 4, 2014, Pages 475-483

  Xu, Jie ^a   Cao, Ke ^a   Li, Yuan ^a   Zou, Xuan ^a   Chen, Cong ^a   Szeto, Ignatius Man Yau ^b   Dong, Zhizhong ^b   Zhao, Youyou ^b   Shi, Yujie ^b   Wang, Junkuan ^b   Liu, Jiankang ^a   Feng, Zhihui ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; DYNAMIN I; INTERLEUKIN 6; MITOCHONDRIAL PROTEIN; MITOFUSIN 1; MOMORDICA CHARANTIA EXTRACT; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID DIET; LIPID STORAGE; LIVER; MALE; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; MOMORDICA CHARANTIA; MOUSE; NONHUMAN; OBESITY; OXIDATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; WEIGHT GAIN; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CHINA; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; FATTY LIVER; FREEZE DRYING; FRUIT; HYPERGLYCEMIA; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPOTROPIC AGENTS; LIVER; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA, LIVER; MOMORDICA CHARANTIA; OBESITY; OXIDATIVE STRESS; RANDOM ALLOCATION;

EID: 84896458830     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.113.187450     Document Type: Article

References (42)

1. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50:204-10.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.
3. Sharabi Y, Eldad A. Nonalcoholic fatty liver disease is associated with hyperlipidemia and obesity. Am J Med. 2000;109:171.
4. Alisi A, Nobili V. Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. Nutrition. 2012;28: 722-6.
5. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95.
6. Czech MP. Obesity notches up fatty liver. Nat Med. 2013;19:969-71.
7. Eberlé D, Hegarty B, Bossard P, Ferre P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86: 839-48.
8. KohjimaM, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med. 2008;21:507-11.
9. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, Kim HH, Yang US, Yu DY, Cheong J. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology. 2007;132:1955-67.
10. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007;22 Suppl 1:S20-7.
11. Venturini D, Simao AN, Scripes NA, Bahls LD, Melo PA, Belinetti FM, Lozovoy MA, Dichi I. Evaluation of oxidative stress in overweight subjects with or without metabolic syndrome. Obesity (Silver Spring). 2012;20:2361-6.
12. Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H, Ota T, Yokoyama M, Honda M, Miyamoto K, et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism. 2008;57:1071-7.
13. Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, Booth FW, et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol. 2010;52:727-36.
14. Platel K, Srinivasan K. Plant foods in the management of diabetes mellitus: vegetables as potential hypoglycaemic agents. Nahrung. 1997; 41:68-74.
15. Krawinkel MB, Keding GB. Bitter gourd (Momordica Charantia): a dietary approach to hyperglycemia. Nutr Rev. 2006;64:331-7.
16. Klomann SD, Mueller AS, Pallauf J, Krawinkel MB. Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice. Br J Nutr. 2010;104:1613-20.
17. Sathishsekar D, Subramanian S. Antioxidant properties of Momordica Charantia (bitter gourd) seeds on streptozotocin induced diabetic rats. Asia Pac J Clin Nutr. 2005;14:153-8.
18. Babu PS, Stanely Mainzen Prince P. Antihyperglycaemic and antioxidant effect of hyponidd, an ayurvedic herbomineral formulation in streptozotocin-induced diabetic rats. J Pharm Pharmacol. 2004;56: 1435-42.
19. Chao CY, Yin MC, Huang CJ. Wild bitter gourd extract up-regulates mRNA expression of PPARalpha, PPARgamma and their target genes in C57BL/6J mice. J Ethnopharmacol. 2011;135:156-61.
20. Sridhar MG, Vinayagamoorthi R, Arul Suyambunathan V, Bobby Z, Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br J Nutr. 2008;99:806-12.
21. Sun L, Shen W, Liu Z, Guan S, Liu J, Ding S. Endurance exercise causes mitochondrial and oxidative stress in rat liver: effects of a combination of mitochondrial targeting nutrients. Life Sci. 2010;86:39-44.
22. Li X, Liu ZB, Luo C, Jia HQ, Sun LJ, Hou B, ShenW, Packer L, Cotman CW, Liu JK. Lipoamide protects retinal pigment epithelial cells from oxidative stress and mitochondrial dysfunction. Free Radic Biol Med. 2008;44:1465-74.
23. Sun L, Luo C, Long HA, Wei DZ, Liu HK. Acrolein is a mitochondrial toxin: effects on respiratory function and enzyme activities in isolated rat liver mitochondria. Mitochondrion. 2006;6:136-42.
24. Yuwai KE, Sundar Rao K, Kaluwin C, Jones GP, Rivett DE. Chemical composition of Momordica charantia L. fruits. J Agric Food Chem. 1991;39:1762-3.
25. Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine. 1996;2: 349-62.
26. Grover JK, Yadav SP. Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol. 2004;93:123-32.
27. Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod. 1981;44:648-55.
28. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S. Antidiabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr. 2009;102:1703-8.
29. Shih CC, Lin CH, Lin WL. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract. 2008;81:134-43.
30. Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr. 2008;100:751-9.
31. Wang ZQ, Zhang XH, Yu Y, Poulev A, Ribnicky D, Floyd ZE, Cefalu WT. Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet-fed mice. J Nutr Biochem. 2011;22:1064-73.
32. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444:860-7.
33. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol. 2013;218:R25-36.
34. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem. 2002;277:19353-7.
35. Ji C, Chan C, Kaplowitz N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol. 2006;45:717-24.
36. Lawler JF Jr, Yin M, Diehl AM, Roberts E, Chatterjee S. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem. 1998;273:5053-9.
37. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol-and obesity-induced fatty liver diseases. Free Radic Biol Med. 2008;44:1259-72.
38. Hao J, Shen W, Tian C, Liu Z, Ren J, Luo C, Long J, Sharman E, Liu J. Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. J Cell Mol Med. 2009;13:701-11.
39. Ritz P, Berrut G. Mitochondrial function, energy expenditure, aging and insulin resistance. Diabetes Metab. 2005;31 Spec No 2:5S67-73.
40. Auwerx J. Improving metabolism by increasing energy expenditure. Nat Med. 2006;12:44-5; discussion, 5.
41. Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013;17:491-506.
42. Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, Smith CL, Youle RJ. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell. 2001;1: 515-25.